本文選題：冠心病 + 糖尿病　； 參考：《廣州醫(yī)科大學(xué)》2017年碩士論文

【摘要】：【研究背景】冠狀動(dòng)脈粥樣硬化性心臟病是指在多種致病因素作用下導(dǎo)致冠狀動(dòng)脈粥樣硬化,引起冠狀動(dòng)脈管腔狹窄甚至閉塞,從而導(dǎo)致心肌細(xì)胞缺血、缺氧或者壞死而引發(fā)的臨床綜合征。有相關(guān)研究表明,內(nèi)皮祖細(xì)胞修復(fù)能力缺陷、血管內(nèi)皮細(xì)胞功能障礙和平滑肌細(xì)胞功能損傷是血管病變的關(guān)鍵環(huán)節(jié)[1]。細(xì)胞膜微囊泡是組織細(xì)胞受到來(lái)自各種不同的刺激反應(yīng)后釋放的一種直徑約為100-1000nm的細(xì)胞膜小囊泡。它在調(diào)節(jié)mi RNA信號(hào)轉(zhuǎn)導(dǎo)和功能表達(dá)中起非常重要的的作用[2]。按照目前研究結(jié)果的觀點(diǎn),普遍認(rèn)為細(xì)胞膜微囊泡是miRNAs的主要載體[3]。miRNAs為長(zhǎng)度大約18-22個(gè)核苷酸的非編碼RNA小分子,它通過抑制蛋白的翻譯或引起mRNA降解,在轉(zhuǎn)錄后的水平上調(diào)控基因表達(dá)。miRNAs通過特異信號(hào)轉(zhuǎn)導(dǎo),可以調(diào)控細(xì)胞周期,對(duì)生物的細(xì)胞分化、增殖凋亡和激素分泌等生物過程有著極其重要的病理生理學(xué)意義。在各種各樣的miRNAs中,很多都與冠心病相關(guān),而miR-155作為炎癥相關(guān)性miRNA,已經(jīng)被證實(shí)參與了冠心病血管內(nèi)皮損傷的發(fā)生發(fā)展。本研究主要采取逆轉(zhuǎn)錄熒光定量PCR(qRT-PCR)檢測(cè)冠心病患者的血miR-155表達(dá)水平,探討miR-155在冠心病發(fā)生發(fā)展中的意義�！狙芯磕康摹刻接懝谛牟』颊叩难獫{細(xì)胞微囊泡miR-155的表達(dá)水平,了解miR-155與冠心病的相關(guān)性。【研究方法】按照本研究的納入及排除標(biāo)準(zhǔn)收集了2014年1月至2016年12月期間于廣州醫(yī)科大學(xué)附屬第二醫(yī)院心血管內(nèi)科住院部92個(gè)病例的外周血標(biāo)本。其中冠心病24例;2型糖尿病21例;冠心病合并糖尿病22例;正常對(duì)照組25例。收集這些患者外周血,分離微囊泡,提取血miR-155,采取逆轉(zhuǎn)錄熒光定量PCR,并且收集這些患者的多項(xiàng)一般臨床指標(biāo)進(jìn)行分析。本研究的所有數(shù)據(jù)均采用SPSS v16.0軟件進(jìn)行統(tǒng)計(jì)分析。統(tǒng)計(jì)方法為單因素方差分析�！窘Y(jié)果】四組患者在性別、年齡、TBIL、DBIL、IBIL、Cr、UA、BNP、LVEF在統(tǒng)計(jì)學(xué)上無(wú)明顯差異(P0.05)。冠心病組患者的CHOL相對(duì)正常對(duì)照組升高(P0.05),LDL-C相對(duì)正常對(duì)照組顯著升高(P0.01)。糖尿病組患者的TG、OGTT 2h、HbA1C及LA相對(duì)正常對(duì)照組升高(P0.05),HDL-C相對(duì)正常對(duì)照組降低(P0.05),收縮壓與冠心病合并糖尿病組比較有統(tǒng)計(jì)學(xué)意義(P0.05)。冠心病合并糖尿病組患者的TG、OGTT2h、Hb A1C及LA相對(duì)正常對(duì)照組升高(P0.05),HDL-C相對(duì)正常對(duì)照組降低(P0.05)。冠心病組及糖尿病組患者的血漿細(xì)胞微囊泡miR-155表達(dá)水平與正常對(duì)照組有明顯統(tǒng)計(jì)學(xué)差異(P0.01),冠心病合并糖尿病組患者的血漿細(xì)胞微囊泡miR-155表達(dá)水平與正常對(duì)照組有統(tǒng)計(jì)學(xué)差異(P0.05)。冠心病組及糖尿病組與冠心病合并糖尿病組比較無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。【結(jié)論】1.冠心病、糖尿病及冠心病合并糖尿病組患者的血漿細(xì)胞膜微囊泡的miR-155表達(dá)水平比較一般人群明顯升高。2.冠心病及糖尿病與冠心病合并糖尿病患者的血漿細(xì)胞膜微囊泡的miR-155表達(dá)水平比較無(wú)差異。
[Abstract]:[background] Coronary atherosclerotic heart disease is defined as coronary atherosclerosis, which can lead to coronary artery stenosis or occlusion, resulting in myocardial ischemia. A clinical syndrome caused by hypoxia or necrosis. Related studies have shown that endothelial progenitor cell repair ability defect vascular endothelial cell dysfunction and smooth muscle cell functional damage is the key link of vascular disease [1]. Cell membrane microvesicle is a kind of cell membrane vesicle about 100-1000nm in diameter which is released by different stimuli of tissue cells. It plays a very important role in regulating mi RNA signal transduction and functional expression [2]. According to the viewpoint of current research results, it is generally believed that cell membrane microvesicles are the main carrier of miRNAs [3] .miRNAs are non-coding RNA small molecules with a length of about 18-22 nucleotides, which inhibit the translation of proteins or cause mRNA degradation. Regulating gene expression. MiRNAs through specific signal transduction at post-transcriptional level can regulate cell cycle and play an important role in biological processes such as cell differentiation, proliferation, apoptosis and hormone secretion. Among all kinds of miRNAs, many miRNAs are related to coronary heart disease (CHD), and miR-155, as inflammation related miRNAs, has been proved to be involved in the occurrence and development of coronary artery disease (CHD) vascular endothelial damage. In this study, the expression of miR-155 in blood of patients with coronary heart disease was detected by reverse transcription fluorescence quantitative PCR (qRT-PCR), and the significance of miR-155 in the occurrence and development of coronary heart disease was discussed. [objective] to investigate the expression level of miR-155 in plasma cell microvesicles of patients with coronary heart disease. To understand the correlation between miR-155 and coronary heart disease. According to the inclusion and exclusion criteria of this study, the peripheral blood samples were collected from 92 patients in the Department of Cardiovascular Medicine of the second affiliated Hospital of Guangzhou Medical University from January 2014 to December 2016. There were 24 cases of coronary heart disease with type 2 diabetes, 22 cases of coronary heart disease with diabetes mellitus and 25 cases of normal control group. The peripheral blood was collected, microvesicles were isolated, blood miR-155 was extracted, reverse transcription fluorescence quantitative PCRs were taken, and some general clinical indexes were collected for analysis. All the data were analyzed by SPSS v16.0 software. [results] there was no significant difference in LVEF between the four groups in sex, age and age (P0.05). Chol in coronary heart disease group was higher than that in normal control group (P0.05) and LDL-C was significantly higher than that in normal control group (P0.01). TGG OGTT 2h HbA1C and LA in diabetic group were higher than those in normal control group (P0.05), HDL-C was lower than normal control group (P0.05), systolic blood pressure (SBP) was significantly higher than that in CHD with diabetes group (P0.05). The levels of HbA1C and LA in CHD with diabetes mellitus group were higher than those in normal control group (P0.05) and HDL-C level was lower than that in normal control group (P0.05). The expression of miR-155 in plasma cell microvesicles in coronary heart disease group and diabetic group was significantly different from that in normal control group (P0.01), and the expression level of plasma cell microvesicular miR-155 in coronary heart disease complicated with diabetes group was significantly different from that in normal control group (P0.05). Coronary heart disease group and diabetes group compared with coronary heart disease combined with diabetes group had no statistical significance (P0.05). [conclusion] 1. The expression of miR-155 in plasma membrane microvesicles in patients with coronary heart disease, diabetes mellitus and coronary heart disease with diabetes mellitus was significantly higher than that in the general population. There was no difference in the expression of miR-155 in plasma membrane microvesicles between patients with coronary heart disease (CHD) and diabetes mellitus (DM) and with diabetes mellitus (CHD).
【學(xué)位授予單位】：廣州醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 高軼;付圣靈;江文洋;李斌峰;田義濤;付向?qū)?;pⅢ期非小細(xì)胞肺癌中miR-155的表達(dá)與預(yù)后關(guān)系的研究[J];中國(guó)肺癌雜志;2014年05期

2 高玲;袁明;鄒清靖;汪雯雯;栗妍;王世宣;;miR-155對(duì)子宮內(nèi)膜間質(zhì)細(xì)胞增殖和凋亡的影響[J];現(xiàn)代婦產(chǎn)科進(jìn)展;2014年01期

3 周長(zhǎng)文;沈顯群;賈駿;王懿釩;冷志宏;羅素新;;糖尿病合并冠心病老年患者氯吡格雷抵抗的危險(xiǎn)因素分析[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

4 劉伏香;譚志琴;龍丹;戈立東;;miR-155在子宮內(nèi)膜癌組織中的表達(dá)及其臨床意義[J];中國(guó)癌癥雜志;2011年09期

5 陳玉芬;;子宮內(nèi)膜癌患者血清中miR-155的表達(dá)及其臨床意義研究[J];中國(guó)醫(yī)藥導(dǎo)刊;2014年01期

6 何培生;劉作金;賈尚瓊;鄭康霞;李冠華;劉磊;黃臻;;miR-155在直腸癌細(xì)胞炎性條件下的表達(dá)[J];胃腸病學(xué)和肝病學(xué)雜志;2014年01期

7 宋顯孝;;降脂湯治療胸痹心痛(痰濁血瘀證)合并高脂血癥的臨床觀察[J];當(dāng)代醫(yī)學(xué);2014年12期

8 劉光全;付菊;;重慶市永川區(qū)老年冠心病合并糖尿病患者的高危因素分析及干預(yù)對(duì)策[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

9 胡艷;肖踐明;;光學(xué)相干斷層成像技術(shù)在冠心病臨界病變中的應(yīng)用[J];臨床醫(yī)學(xué);2014年05期

10 王娟;俞力;范鈺;;miR-155反義寡核苷酸轉(zhuǎn)染對(duì)甲狀腺癌細(xì)胞遷移、侵襲和MMP-13表達(dá)的影響[J];江蘇大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年06期

相關(guān)重要報(bào)紙文章 前1條

1 楊曉紅;農(nóng)藥微囊劑型為何難推廣[N];農(nóng)資導(dǎo)報(bào);2010年

相關(guān)博士學(xué)位論文 前7條

1 楊龍龍;miR-155在創(chuàng)面愈合中的作用及機(jī)制研究[D];第四軍醫(yī)大學(xué);2015年

2 王吉元;心衰1號(hào)方治療高血壓病、糖尿病、冠心病并發(fā)慢性心衰的臨床研究[D];中國(guó)中醫(yī)科學(xué)院;2017年

3 高明柯;基于增強(qiáng)現(xiàn)實(shí)的冠心病血管介入手術(shù)仿真培訓(xùn)中關(guān)鍵問題研究[D];上海大學(xué);2017年

4 李健;miR-155真核表達(dá)載體的構(gòu)建及其在胰腺癌中功能的初步研究[D];中國(guó)協(xié)和醫(yī)科大學(xué);2008年

5 葉金善;miR-155調(diào)控PDCD4的炎癥反應(yīng)影響粥樣斑塊穩(wěn)定性的機(jī)制研究[D];第三軍醫(yī)大學(xué);2017年

6 張光遠(yuǎn);人臍帶間質(zhì)干細(xì)胞分泌的微囊減輕大鼠缺血再灌注引發(fā)的急、慢性腎損傷的機(jī)制研究[D];上海交通大學(xué);2015年

7 鄧輔財(cái);芘降解菌層層自組裝微囊固定化及其促降解的作用機(jī)制[D];華南理工大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 熊振宇;冠心病患者血漿細(xì)胞膜微囊泡miR-155表達(dá)的分析[D];廣州醫(yī)科大學(xué);2017年

2 沈忱;白介素-37與冠心病的相關(guān)性及其在疾病中的作用研究[D];暨南大學(xué);2017年

3 任云霞;冠心病合并亞臨床甲狀腺功能減退癥患者的臨床特點(diǎn)及預(yù)后[D];山西醫(yī)科大學(xué);2017年

4 唐天娜;張明雪教授從陽(yáng)虛論治冠心病合并慢性腎臟病的經(jīng)驗(yàn)總結(jié)[D];遼寧中醫(yī)藥大學(xué);2017年

5 梅湘凝;中性粒細(xì)胞/淋巴細(xì)胞比值、脂蛋白相關(guān)磷脂酶A2與2型糖尿病伴冠心病的相關(guān)性研究[D];鄭州大學(xué);2017年

6 董靜璇;載脂蛋白E基因與冠心病患者的相關(guān)性研究[D];山西醫(yī)科大學(xué);2017年

7 鄒冰;探討頸動(dòng)脈內(nèi)中膜厚度及斑塊與冠心病的相關(guān)性[D];山西醫(yī)科大學(xué);2017年

8 賈學(xué)文;CYP17A1基因多態(tài)性與冠心病的研究[D];青島大學(xué);2017年

9 楊世艷;基于內(nèi)皮損傷學(xué)說(shuō)的冠心病中藥干預(yù)研究[D];遼寧中醫(yī)藥大學(xué);2017年

10 單舒文;豬miR-155兩種基因型的性狀關(guān)聯(lián)分析的研究[D];華中農(nóng)業(yè)大學(xué);2016年

，

本文編號(hào)：2056152